Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed FCF Margin for 8 consecutive years, with 224.28% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 22303.0% year-over-year to 224.28%, compared with a TTM value of 90.82% through Dec 2025, down 5117.0%, and an annual FY2025 reading of 90.82%, down 5117.0% over the prior year.
  • FCF Margin was 224.28% for Q4 2025 at Arcturus Therapeutics Holdings, down from 101.05% in the prior quarter.
  • Across five years, FCF Margin topped out at 484.09% in Q2 2023 and bottomed at 2024.82% in Q1 2021.
  • Average FCF Margin over 5 years is 335.39%, with a median of 88.02% recorded in 2025.
  • The sharpest move saw FCF Margin tumbled -157131bps in 2021, then soared 150949bps in 2022.
  • Year by year, FCF Margin stood at 791.22% in 2021, then soared by 113bps to 101.34% in 2022, then plummeted by -96bps to 4.31% in 2023, then crashed by -129bps to 1.25% in 2024, then plummeted by -17879bps to 224.28% in 2025.
  • Business Quant data shows FCF Margin for ARCT at 224.28% in Q4 2025, 101.05% in Q3 2025, and 20.33% in Q2 2025.